Ambu (AMBU-B) Stock Price, Fundamentals & Analysis

What AMBU-B does

Ambu (AMBU-B) is a Danish medical device company that designs, manufactures, and sells single-use and reusable products for airway management, endoscopy, neurology, cardiology, emergency care, and patient monitoring. Headquartered in Ballerup, Denmark, the company operates in North America, Europe, and other international markets. Its product portfolio includes bronchoscopes, video laryngoscopes, ECG electrodes, breathing bags, resuscitators, and training manikins for healthcare professionals. With 5,200 employees, Ambu serves hospitals, clinics, and defense imaging OEMs worldwide.

Key numbers explained

• Price: 68,2 DKK — the most recent trading price of one share on the Nasdaq Copenhagen.
• Market cap: 17,79 mld. DKK — the total market value of all outstanding shares, placing Ambu among the larger Danish healthcare companies alongside peers such as Coloplast (COLO-B) and GN Store Nord (GN).
• Trailing P/E ratio: 35,5 — the current share price divided by the last twelve months' earnings per share; a higher P/E can reflect expectations of future growth.
• Forward P/E ratio: 22,5 — the price relative to expected future earnings, which can differ from the trailing P/E if analysts forecast a change in profitability.
• Dividend yield: 0,6% — the annual dividend as a percentage of the share price, indicating the cash return to shareholders from dividends.
• Ex-dividend date: 4 dec. 2025 — the date after which a buyer is no longer entitled to the next dividend payment.
• Share of earnings paid out as dividends: 21% — roughly one-fifth of the company's earnings is returned to shareholders as dividends.
• Beta: 1,39 — a measure of the stock's volatility relative to the market; a beta above 1 suggests the share tends to move more than the overall market.
• 52-week range: 56,25 – 111,8 DKK — the lowest and highest prices seen over the past year, showing the stock's recent trading range.
• Price change over the last 52 weeks: -27,3% — the percentage decline from the price one year ago to the current level.
• Revenue, trailing 12 months: 6,24 mld. DKK — the total sales over the past twelve months.
• Revenue growth, year over year: 8,8% — the annual percentage increase in revenue.
• Profit margin: 8,2% — the percentage of revenue that remains as profit after all expenses.
• Operating margin: 13,5% — the percentage of revenue left after covering operating costs, before interest and taxes.
• Return on equity: 8,4% — the annual return generated on shareholders' equity.
• Debt-to-equity ratio: 9,4% — the proportion of debt relative to equity, indicating a relatively low level of leverage.
• Price-to-book: 2,92 — the market price per share divided by the book value per share.
• Next earnings date: 5 nov. 2026 — the scheduled date for the company's next earnings release.

What to watch

Investors tracking Ambu may consider factors common to the healthcare and medical device sector. Regulatory approvals and changes in reimbursement policies can affect product adoption and margins. Currency fluctuations matter because Ambu operates internationally, and the Danish krone's movements can influence reported results. R&D spending and innovation cycles are relevant for a company whose products include endoscopy, neurology, and airway management devices. Competitive dynamics with other medical device makers, as well as broader trends in hospital capital expenditure, can also shape the company's outlook. Ambu is part of the Nasdaq Copenhagen stocks universe and is sometimes discussed alongside Danish healthcare names such as Genmab (GMAB), Zealand Pharma (ZEAL), and Novo Nordisk (NOVO-B).